Clinical trial NCT02870634: Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
Official title: A Phase 1 Single and Multiple Dose Escalation and Pharmacokinetic Study of Cu(II)ATSM Administered Orally to Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Lead sponsor: Collaborative Medicinal Development Pty Limited
Sponsor class: INDUSTRY
First posted: 2016-08-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Multicenter, open-label , single and multiple dose-escalation and pharmacokinetic study

Detailed description: Multicenter, open-label, phase 1 study of Cu(II)ATSM administered orally to patients wit amyotrophic lateral sclerosis/motor neuron disease. The study will be conducted in three phases. In the first two phases, dose cohorts of six patients each will participate in a single dose pharmacokinetic study followed by a 28-day repeated daily dose study to establish the recommended phase 2 dose (RP2D). The first dose cohort will be treated at 3 mg/day; planned dose escalations are 6, 12, 24, and 48 mg/day, subject to observed safety assessments. In the third phase of the study, participants will be treated at the RP2D to confirm tolerability and assess preliminary evidence of efficacy.

In both the dose escalation and expansion cohorts, once the first 28 days of treatment and assessments are completed, at the discretion of the investigator a patient may continue to receive Cu(II)ATSM treatment for a maximum of six 28-day treatment cycles.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent prior to initiation of any study-specific procedures;
* Familial or sporadic ALS/MND defined as clinically possible, probable, or definite by Awaji-shima Consensus Recommendations;
* First ALS/MND symptoms occurred no more than 2 years prior to screening visit;
* Seated FVC ≥ 70% and SNP ≥ 50% of predicted value;
* Not taking riluzole or on a stable dose of riluzole for at least 4 weeks prior to screening visit (participants are not allowed to start taking riluzole during the study);
* Age between 18 and 75 years at time of informed consent;
* Patient has a competent caregiver who can and will be responsible for administration of study drug;
* Adequate bone marrow reserve, renal and liver function:

  * absolute neutrophil count ≥ 1500/µL
  * lymphocyte count \< 48%
  * platelet count ≥ 150,000/µL
  * hemoglobin ≥ 11 g/dL
  * creatinine clearance ≥ 60 mL/min (Cockroft \& Gault formula)
  * ALT and/or AST ≤ 2 x ULN
  * total bilirubin ≤ 1.5 x ULN
  * serum albumin ≥ 2.8 g/dL
* Women and men with partners of childbearing potential must take effective contraception while on study and women of childbearing potential must have a negative pregnancy test and be non-lactating at screening

Exclusion Criteria:

* Inability to swallow oral medications or presence of GI disorder deemed to jeopardize intestinal absorption of Cu(II)ATSM
* Dependence of mechanical ventilation (non-invasive or invasive) for any part of day or night
* Exposure to any other investigational agent within 3 months or two investigational agents within 6 months prior to screening visit
* Active GI disease (except gastrointestingal reflux disease) within 30 days of screening visit
* Known immune compromising illness or treatment
* Presence of any of the following clinical conditions

  * drug abuse or alcoholism
  * unstable cardiac, pulmonary, renal, hepatic, endocrine or hematologic disorder
  * active infectious disease
  * AIDS or AIDS-related complex
  * current malignancy
  * unstable psychiatric illness, defined as psychosis or untreated major depression within 90 days of screening visit
  * neuromuscular disease other than ALS/MND
* Dementia that may affect either outcome measures or patient understanding and/or compliance with study requirements and procedures
* Use of anticoagulants at therapeutic doses within 7 days prior to screening visit
* Current use of strong inducers or inhibitors of CYPs 2C19 and 2D6

Primary outcomes:
measure: recommended phase 2 dose as determined by the number of participants at each dose level with dose limiting toxicities
timeFrame: 24 months
Secondary outcomes:
measure: Treatment-related change in disease severity by ALS Functional Rating Scale - Revised (ALSFRS-R)
timeFrame: 24 months
measure: Treatment-related change in cognitive function by Edinburgh Cognitive and Behavioral Assessment (ECAS) score
timeFrame: 24 months
measure: Treatment-related change in respiratory function by seated forced vital capacity (FCV)
timeFrame: 24 months
measure: Treatment-related change in quality of life by ALSSQOL-R score
timeFrame: 24 months
measure: Treatment-related change in disease severity by transcranial magnetic stimulation (TMS) response
timeFrame: 24 months
measure: Peak Cu(II)ATSM plasma concentration following administration of a single dose based on blood draws taken at 1, 2, 4, 8 and 24 hours after dosing
timeFrame: 12 months
measure: Area under the Cu(II)ATSM plasma concentration versus time curve (AUC) following administration of a single dose based on blood draws taken at 1, 2, 4, 8 and 24 hours after dosing
timeFrame: 12 months
measure: Treatment-related change in respiratory function by sniff nasal pressure (SNP) test
timeFrame: 24 months
Other outcomes:
Locations:
city: Sydenham
country: Australia
facility: Macquarie University
state: New South Wales
city: Caulfield
country: Australia
facility: Calvary Health Care Bethlehem
state: Victoria
Study officials:
affiliation: Macquarie University
name: Dominic Rowe, MD
role: PRINCIPAL_INVESTIGATOR
References: